2021
Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings
Noyan H, Erdağ E, Tüzün E, Yaylım İ, Küçükhüseyin Ö, Hakan M, Gülöksüz S, Rutten B, Saka M, Atbaşoğlu C, Alptekin K, van Os J, Üçok A. Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings. Schizophrenia Research 2021, 229: 27-37. PMID: 33609988, DOI: 10.1016/j.schres.2021.01.014.Peer-Reviewed Original ResearchConceptsSchizophrenia spectrum disordersIL-1β levelsKYNA levelsHigher serum IL-1β levelsSerum IL-1β levelsHigher KYNA levelsTrp-Kyn pathwayKynurenic acid levelsSimilar clinical featuresPathophysiology of schizophreniaManifestations of schizophreniaKYN levelsSerum interleukinClinical featuresInflammatory cytokinesIL-1βClinical dataKynurenine pathwayTRP levelsSpectrum disorderControl groupAdvanced stageLow TrpPathway dysregulationPatients
2013
Clinical potential of cariprazine in the treatment of acute mania.
Altınbaş K, Guloksuz S, Oral E. Clinical potential of cariprazine in the treatment of acute mania. Psychiatria Danubina 2013, 25: 207-13. PMID: 24048386.Peer-Reviewed Original ResearchConceptsAcute manic episodeAdverse eventsManic episodesTreatment-emergent adverse eventsD3 receptor activityFlexible-dose studyCommon adverse eventsSerious adverse eventsCommon side effectsAdditional therapeutic benefitSecond-generation antipsychoticsCariprazine treatmentDopamine agonismPlacebo armAcute maniaExtrapyramidal symptomsQTc prolongationGeneration antipsychoticsHistamine H1Novel antipsychoticsProlactin increaseMetabolic disturbancesClinical trialsClinical dataDopamine D2